Astrana Health’s Growth Counters a Decline in Capital Returns
StockStory sees Astrana Health’s long-term sales and earnings growth as positives, while warning that its return on invested capital has fallen.
Key takeaways
- Astrana Health’s sales grew at a 40.2% annualized rate over five years, according to StockStory.
- StockStory said the company’s return on invested capital has declined in recent years.
StockStory said Astrana Health’s positive attributes outweigh its risks after the healthcare company’s shares gained 35.1% over six months. The publisher cited long-term sales and earnings growth, but also flagged a decline in return on invested capital.
Astrana’s sales grew at a 40.2% compounded annual rate over five years, while earnings per share rose at an 11.6% rate, according to StockStory. The publisher said the company’s return on invested capital had decreased significantly in recent years.
StockStory put the shares at $37.03 and valued them at 11.1 times forward earnings. As of 15:33 UTC Thursday, shares traded at $36.15, down 2.67% since the previous close.
This article was produced with the help of AI technology. Source: Yahoo Finance
